| Year |
Citation |
Score |
| 2024 |
Radtke AJ, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, Meerson M, Polyakova M, Galkin I, Svekolkin V, Isaev S, Wiebe D, Sharun A, Sarachakov A, Perelman G, ... ... Nomie K, et al. Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. Cancer Cell. PMID 38428410 DOI: 10.1016/j.ccell.2024.02.001 |
0.321 |
|
| 2023 |
Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, Fetooh A, Kanagal-Shamanna R, Vega F, Bagaev A, Fowler N, Flowers CR, Wang M. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer Journal. 13: 156. PMID 37821434 DOI: 10.1038/s41408-023-00927-2 |
0.311 |
|
| 2022 |
Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discovery. PMID 35687817 DOI: 10.1158/2643-3230.BCD-21-0075 |
0.317 |
|
| 2021 |
Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, ... ... Nomie K, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Communications. 12: 2877. PMID 34001881 DOI: 10.1038/s41467-021-22872-z |
0.391 |
|
| 2021 |
Razzaghi R, Agarwal S, Kotlov N, Plotnikova O, Nomie K, Huang DW, Wright GW, Smith GA, Li M, Takata K, Yamadi M, Yao C, O'Shea JJ, Phelan JD, Pittaluga S, et al. Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma. The Journal of Experimental Medicine. 218. PMID 33237303 DOI: 10.1084/jem.20201173 |
0.323 |
|
| 2020 |
Guo WH, Qi X, Yu X, Liu Y, Chung CI, Bai F, Lin X, Lu D, Wang L, Chen J, Su LH, Nomie KJ, Li F, Wang MC, Shu X, et al. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nature Communications. 11: 4268. PMID 32848159 DOI: 10.1038/S41467-020-17997-6 |
0.315 |
|
| 2020 |
Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Advances. 4: 2927-2938. PMID 32598477 DOI: 10.1182/Bloodadvances.2019001350 |
0.356 |
|
| 2020 |
Zhao S, Kanagal-Shamanna R, Navsaria L, Chi Young OK, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. American Journal of Hematology. PMID 32239765 DOI: 10.1002/Ajh.25796 |
0.473 |
|
| 2020 |
Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances. 4: 1038-1050. PMID 32191807 DOI: 10.1182/Bloodadvances.2019001396 |
0.334 |
|
| 2020 |
Nomie K, Jain P, Kotlov N, Segodin V, Cai Q, Liu Y, Navsaria L, Svekolkin V, Bagaev A, Frenkel F, Ataullakhanov R, Fowler NH, Wang M. Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma. Journal of Clinical Oncology. 38: e20065-e20065. DOI: 10.1200/Jco.2020.38.15_Suppl.E20065 |
0.459 |
|
| 2020 |
Kim E, Miheecheva N, Ramachandran A, Lyu Y, Galkin I, Svekolkin V, Postovalova E, Bagaev A, Nomie K, Ogloblina A, Frenkel F, Ataullakhanov R, Hsieh JJ, Pachynski RK. Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. Journal of Clinical Oncology. 38: e17506-e17506. DOI: 10.1200/Jco.2020.38.15_Suppl.E17506 |
0.331 |
|
| 2020 |
Hsieh JJ, Miheecheva N, Ramachandran A, Lyu Y, Galkin I, Svekolkin V, Postovalova E, Bagaev A, Lozinsky Y, Zyrin V, Zaitsev A, Nuzhdina K, Nomie K, Ogloblina A, Frenkel F, et al. Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma. Journal of Clinical Oncology. 38: e17106-e17106. DOI: 10.1200/Jco.2020.38.15_Suppl.E17106 |
0.365 |
|
| 2020 |
Nomie K, Jain P, Kotlov N, Segodin V, Cai Q, Liu Y, Navsaria L, Svekolkin V, Bagaev A, Frenkel F, Ataullakhanov R, Fowler NH, Wang M. Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance. Journal of Clinical Oncology. 38: 8055-8055. DOI: 10.1200/Jco.2020.38.15_Suppl.8055 |
0.424 |
|
| 2020 |
Raju Paul S, Kotlov N, Svekolkin V, Frenkel F, Almog N, Tsiper M, Nomie K, Fowler NH, Lin D, Valine L, Sluder A, Bagaev A, Ataullakhanov R, Poznansky MC, Wirth LJ. Immune functional portraits of head and neck cancer using next generation sequencing. Journal of Clinical Oncology. 38: 6561-6561. DOI: 10.1200/Jco.2020.38.15_Suppl.6561 |
0.314 |
|
| 2020 |
Yao Y, Li L, Zhang L, Zhang S, Guo H, Zhang H, Badillo M, Chen Z, Hartig K, Jain P, Nomie K, Wang L, Wang M. Abstract 652: Exploiting PRMT5, a metabolic and epigenetic regulator, as a novel therapeutic target in mantle cell lymphoma Cancer Research. 80: 652-652. DOI: 10.1158/1538-7445.Am2020-652 |
0.475 |
|
| 2020 |
Jiang C, Zhang S, Wang Y, Zhang R, Liu Y, McIntosh J, Han G, Wang R, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Lee H, ... ... Nomie K, et al. Abstract 5683: Single-cell RNA-seq reveals heterogeneity, clonal evolution and strategies to overcome ibrutinib-venetoclax dual resistance in mantle cell lymphoma Cancer Research. 80: 5683-5683. DOI: 10.1158/1538-7445.Am2020-5683 |
0.51 |
|
| 2019 |
Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, ... ... Nomie K, et al. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer Journal. 9: 95. PMID 31780660 DOI: 10.1038/S41408-019-0259-8 |
0.394 |
|
| 2019 |
Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, et al. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia. PMID 31123343 DOI: 10.1038/S41375-019-0489-6 |
0.476 |
|
| 2019 |
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, ... ... Nomie K, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine. 11. PMID 31068440 DOI: 10.1126/Scitranslmed.Aau1167 |
0.441 |
|
| 2019 |
Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Science Signaling. 12. PMID 30723172 DOI: 10.1126/Scisignal.Aat4105 |
0.483 |
|
| 2019 |
Liu Y, Zhao S, Jiang C, Yao Y, Murfin KP, Grundman H, Zhang L, Nomie K, Wang L, Wang M. The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma Blood. 134: 1487-1487. DOI: 10.1182/Blood-2019-131079 |
0.534 |
|
| 2019 |
Nomie K, Kotlov N, Svekolkin V, Bagaev A, Cai Q, Falahat J, Moghrabi O, Frenkel F, Attaulakhanov R, Leeming A, Jung D, Hill H, Murfin KP, Chen Z, Hartig K, et al. Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma Blood. 134: 2762-2762. DOI: 10.1182/Blood-2019-130512 |
0.474 |
|
| 2019 |
Jiang C, Zhang S, Wang Y, Zhang R, Liu Y, McIntosh JM, Han G, Wang R, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Lee HJ, ... ... Nomie K, et al. Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq Blood. 134: 5217-5217. DOI: 10.1182/Blood-2019-129134 |
0.519 |
|
| 2019 |
Jiang C, Zhang S, Huang S, Liu Y, Zhang R, Leeming A, McIntosh JM, Lee W, Nomie K, Wang L, Wang ML. Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma Blood. 134: 3974-3974. DOI: 10.1182/Blood-2019-128810 |
0.472 |
|
| 2019 |
Jiang C, Zhang R, Zhang S, Lee W, Huang S, Liu Y, Leeming A, McIntosh JM, Jain P, Nomie K, Wang L, Wang ML. Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma Blood. 134: 4062-4062. DOI: 10.1182/Blood-2019-128299 |
0.539 |
|
| 2019 |
Jiang C, Liu Y, McIntosh JM, Leeming A, Zhang R, Lee W, Nomie K, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang ML. BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma Blood. 134: 2863-2863. DOI: 10.1182/Blood-2019-126957 |
0.52 |
|
| 2019 |
Yao Y, Liu Y, Zhang H, Leeming A, McIntosh JM, Jain P, Zhang L, Nomie K, Wang ML. Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma Blood. 134: 1506-1506. DOI: 10.1182/Blood-2019-126738 |
0.445 |
|
| 2019 |
Jain P, Zhao S, Kanagal-Shamanna R, Navsaria L, Hill H, Misra A, Nomie K, Jiang C, Yao Y, Zhang L, Nastoupil LJ, Hagemeister FB, Westin JR, Nair R, Steiner RE, et al. Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL Blood. 134: 2815-2815. DOI: 10.1182/Blood-2019-126175 |
0.403 |
|
| 2019 |
Wang ML, Jain P, Lee HJ, Hagemeister FB, Samaniego F, Westin JR, Nastoupil LJ, Chen W, Nomie K, Zhang S, Moghrabi O, Zhao S, Kanagal-Shamanna R, Ok CY, Oriabure O, et al. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial Blood. 134: 3987-3987. DOI: 10.1182/Blood-2019-126044 |
0.368 |
|
| 2019 |
Jain P, Kanagal-Shamanna R, Ok CY, Omarya G, Navsaria L, Nogueras González GM, Zhang S, Han G, Ghorab A, Boddu P, Hagemeister FB, Lee HJ, Nomie K, Jiang C, Fayad L, et al. Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients Blood. 134: 1526-1526. DOI: 10.1182/Blood-2019-125936 |
0.354 |
|
| 2019 |
Zhang L, Guo H, Zhang H, Yao Y, Liu Y, Zhang S, Rui L, Wang L, Nomie K, Wang ML. Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma Blood. 134: 395-395. DOI: 10.1182/Blood-2019-125934 |
0.53 |
|
| 2019 |
Jain P, Lee HJ, Steiner RE, Hagemeister FB, Samaniego F, Westin JR, Nastoupil LJ, Ahmed S, Iyer SP, Romaguera JE, Zhao S, Nomie K, Ok CY, Kanagal-Shamanna R, Oriabure O, et al. Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial Blood. 134: 3988-3988. DOI: 10.1182/Blood-2019-125800 |
0.373 |
|
| 2019 |
Guo H, Zhang H, Nomie K, Zhang L, Murfin KP, Wang M. Abstract 3702: Establishment and characterization of a novelMYC/BCL2double-hit high-grade B-cell lymphoma cell line HLA-3 Cancer Research. 79: 3702-3702. DOI: 10.1158/1538-7445.Sabcs18-3702 |
0.431 |
|
| 2019 |
Liu Y, Nomie K, Jiang C, Yao Y, Zhang L, Wang M. Molecular Profiling plus In Vitro and In Vivo Drug Efficacy Analyses Identifies Novel Treatments to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma Clinical Lymphoma Myeloma and Leukemia. 19: S318. DOI: 10.1016/J.Clml.2019.07.295 |
0.426 |
|
| 2019 |
Zhang R, Lee W, Huang S, Liu Y, Leeming A, McIntosh J, Nomie K, Jiang C, Wang M. COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB-VENETOCLAX RESISTANCE VIA TARGETING PI3K-AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA Hematological Oncology. 37: 126-127. DOI: 10.1002/Hon.86_2629 |
0.422 |
|
| 2019 |
Jain P, Kanagal-Shamanna R, Zhang S, Ok C, Nogueras Gonzalez G, Gonzalez-Pagan O, Ghorab A, Boddu P, Chen W, Lee HJ, Nomie K, Fayad L, Westin J, Nastoupil L, Patel K, et al. COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA Hematological Oncology. 37: 238-239. DOI: 10.1002/Hon.49_2630 |
0.368 |
|
| 2019 |
Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, Nogueras Gonzales G, Zhang L, Wagner-Bartak N, Hagemeister F, Samaniego F, Westin J, Lee H, Nastoupil L, Ok C, et al. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL) Hematological Oncology. 37: 42-43. DOI: 10.1002/Hon.12_2629 |
0.348 |
|
| 2019 |
Jain P, Romaguera J, Nomie K, Zhang S, Wang L, Oriabure O, Wagner-Bartak N, Zhang L, Hagemeister F, Samaniego F, Westin J, Ju Lee H, Nastoupil L, Iyer S, Parmar S, et al. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) - PHASE II TRIAL Hematological Oncology. 37: 42-42. DOI: 10.1002/Hon.11_2629 |
0.36 |
|
| 2018 |
Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Molecular Cancer Therapeutics. PMID 30413649 DOI: 10.1158/1535-7163.Mct-18-0478 |
0.497 |
|
| 2018 |
Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, et al. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. PMID 30361685 DOI: 10.1038/S41388-018-0550-3 |
0.489 |
|
| 2018 |
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology. PMID 30175400 DOI: 10.1111/Bjh.15567 |
0.38 |
|
| 2018 |
Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang ML. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. Journal of Experimental & Clinical Cancer Research : Cr. 37: 150. PMID 30005678 DOI: 10.1186/S13046-018-0800-9 |
0.412 |
|
| 2018 |
Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. Journal of Hematology & Oncology. 11: 83. PMID 29907126 DOI: 10.1186/S13045-018-0621-5 |
0.475 |
|
| 2018 |
Merolle MI, Ahmed M, Nomie K, Wang ML. The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget. 9: 25332-25341. PMID 29861875 DOI: 10.18632/Oncotarget.25011 |
0.414 |
|
| 2018 |
Ye H, Desai A, Gong T, Zeng D, Nomie K, Chen W, Wang W, Romaguera J, Wang ML. Spontaneous regression of mantle cell lymphoma: a report of four cases. Cancer Communications (London, England). 38: 30. PMID 29843782 DOI: 10.1186/S40880-018-0306-Z |
0.402 |
|
| 2018 |
Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin JR, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29666304 DOI: 10.1158/1078-0432.Ccr-17-3004 |
0.466 |
|
| 2018 |
Wharton TH, Nomie KJ, Wharton RP. No significant regulation of bicoid mRNA by Pumilio or Nanos in the early Drosophila embryo. Plos One. 13: e0194865. PMID 29601592 DOI: 10.1371/Journal.Pone.0194865 |
0.59 |
|
| 2018 |
Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M. Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). American Journal of Clinical Oncology. PMID 29419530 DOI: 10.1097/Coc.0000000000000427 |
0.483 |
|
| 2018 |
Guo H, Yao Y, Zhang H, Lorence E, Ahmed M, Ping L, Nomie K, Zhang L, Wang M. FoxM1-Mediated Signaling Promotes the Progression of Mantle Cell Lymphoma Blood. 132: 4176-4176. DOI: 10.1182/Blood-2018-99-119349 |
0.54 |
|
| 2018 |
Nomie K, Zhang L, Yao Y, Liu Y, Zhang S, Zhang H, Guo H, Ahmed M, Badillo M, Wang L, Wang M. Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos Blood. 132: 41-41. DOI: 10.1182/Blood-2018-99-117279 |
0.552 |
|
| 2018 |
Ye H, Huang S, Jung D, Jiang C, Nomie K, Zhang L, Wang M. Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Blood. 132: 2950-2950. DOI: 10.1182/Blood-2018-99-117013 |
0.539 |
|
| 2018 |
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Nogueras González GM, Ahmed M, Omarya G, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, et al. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients Blood. 132: 1599-1599. DOI: 10.1182/Blood-2018-99-115360 |
0.368 |
|
| 2018 |
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel K, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, et al. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib Blood. 132: 4151-4151. DOI: 10.1182/Blood-2018-99-115179 |
0.42 |
|
| 2018 |
Zhang L, Zhang H, Guo H, Sun Y, Feng N, Marszalek JR, Ahmed M, Nomie K, Wang M. A Novel Patient-Derived Xenograft Model of Secondary CD20- CNS Lymphoma for Mechanistic and Therapeutic Exploration Blood. 132: 1669-1669. DOI: 10.1182/Blood-2018-99-112205 |
0.433 |
|
| 2018 |
Yao Y, Liu Y, Guo H, Ahmed M, Bhuiyan S, Nomie K, Zhang L, Wang M. Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma Blood. 132: 2945-2945. DOI: 10.1182/Blood-2018-99-112192 |
0.447 |
|
| 2018 |
Ahmed M, Guo H, Zhang S, Sehgal L, Jain P, Kanagal-Shamanna R, Ok CY, Leeming A, Yao Y, Zhang L, Nomie K, Wang L, Wang M. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing Blood. 132: 4118-4118. DOI: 10.1182/Blood-2018-99-110540 |
0.471 |
|
| 2018 |
Jiang C, Huang S, Liu Y, Nomie K, Zhang L, Wang M. Abstract 3459: Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma Cancer Research. 78: 3459-3459. DOI: 10.1158/1538-7445.Am2018-3459 |
0.524 |
|
| 2018 |
Ahmed M, Lorence E, Guo H, Huang S, Zhang V, Zhang H, Zhang L, Nomie K, Wang M. Abstract 1981: Pan-cancer pathways gene expression profiling in mantle cell lymphoma reveals upregulation of DNA damage repair genes in ibrutinib-resistant tumor Cancer Research. 78: 1981-1981. DOI: 10.1158/1538-7445.Am2018-1981 |
0.442 |
|
| 2017 |
Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML. Smoldering mantle cell lymphoma. Journal of Experimental & Clinical Cancer Research : Cr. 36: 185. PMID 29246179 DOI: 10.1186/S13046-017-0652-8 |
0.411 |
|
| 2017 |
Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer Journal. 7: 632. PMID 29167454 DOI: 10.1038/S41408-017-0005-Z |
0.443 |
|
| 2017 |
Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. European Journal of Medicinal Chemistry. 138: 543-551. PMID 28704757 DOI: 10.1016/J.Ejmech.2017.06.067 |
0.442 |
|
| 2017 |
Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, et al. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. The Oncologist. PMID 28408615 DOI: 10.1634/theoncologist.2016-0328 |
0.318 |
|
| 2017 |
Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang ML. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. British Journal of Haematology. PMID 28369820 DOI: 10.1111/Bjh.14669 |
0.457 |
|
| 2017 |
Zhang L, Nomie K, Zhang H, Bell T, Pham LV, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28348046 DOI: 10.1158/1078-0432.Ccr-16-2703 |
0.445 |
|
| 2017 |
Jiang C, Huang S, Liu Y, Li C, Guo H, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Lin X, Zhang L, et al. Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients Blood. 130: 574-574. DOI: 10.1182/Blood.V130.Suppl_1.574.574 |
0.535 |
|
| 2017 |
Huang S, Jiang C, Guo H, Wang J, Liu Y, Li C, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Zhang L, Wang M. Resistance Mechanisms Underlying Venetoclax Resistance in Mantle Cell Lymphoma Blood. 130: 2749-2749. DOI: 10.1182/Blood.V130.Suppl_1.2749.2749 |
0.482 |
|
| 2017 |
Huang S, Bell T, Liu Y, Guo H, Li C, Ahmed M, Lam L, Zhang H, Chen Z, Wang ML, Zhang L, Nomie K. Abstract 3651: Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma Cancer Research. 77: 3651-3651. DOI: 10.1158/1538-7445.Am2017-3651 |
0.463 |
|
| 2017 |
Chen W, Zeng D, Desai A, Badillo M, Feng L, Yan F, Nomie K, Ping L, Ye H, Liang Y, Lee H, Oki Y, Romaguera J, Wang M. Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease Hematological Oncology. 35: 360-360. DOI: 10.1002/Hon.2439_114 |
0.379 |
|
| 2017 |
Wang M, Lee H, Thirumurthi S, Chuang H, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Oriabure O, Feng L, Zhou S, Huang S, Li S, ... ... Nomie K, et al. IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO Hematological Oncology. 35: 142-143. DOI: 10.1002/hon.2437_132 |
0.333 |
|
| 2016 |
Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M. ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. Critical Reviews in Oncology/Hematology. 107: 14-19. PMID 27823642 DOI: 10.1016/J.Critrevonc.2016.08.008 |
0.433 |
|
| 2016 |
Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget. PMID 27449094 DOI: 10.18632/Oncotarget.10716 |
0.446 |
|
| 2016 |
Li CJ, Liu Y, Bell T, Wang J, Guo H, Ahmed M, Zhang H, Lam LT, Nomie K, Wang L, Zhang L, Wang M. Novel Bruton's Tyrosine Kinase Inhibitor Bgb-3111 Demonstrates Potent Activity in Mantle Cell Lymphoma Blood. 128: 5374-5374. DOI: 10.1182/Blood.V128.22.5374.5374 |
0.507 |
|
| 2016 |
Boyle JN, Kim CR, Guo H, Bell T, Huang S, Li CJ, Liu Y, Zhang H, Wang J, Zhang V, Ahmed M, Lam LT, Nomie K, Zhang L, Zeng D, et al. CUDC-907: An Oral HDAC/PI3K Dual Inhibitor with Strong Preclinical Efficacy in MCL Model Blood. 128: 4183-4183. DOI: 10.1182/Blood.V128.22.4183.4183 |
0.516 |
|
| 2016 |
Liu Y, Bell T, Zhang H, Sun Y, Li CJ, Feng N, Huang S, Guo H, Wang J, Ahmed M, Zhang V, Lam LT, Nomie K, Zhang L, Di Francesco ME, et al. Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma Blood. 128: 290-290. DOI: 10.1182/Blood.V128.22.290.290 |
0.54 |
|
| 2016 |
Bell T, Zhang H, Ahmed M, Guo H, Li CJ, Liu Y, Lam LT, Chen Z, Wang J, Zhang V, Nomie K, Zhang L, Wang M. Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial Blood. 128: 1839-1839. DOI: 10.1182/Blood.V128.22.1839.1839 |
0.526 |
|
| 2016 |
Guo H, Huang S, Liu Y, Li CJ, Wang J, Zhang V, Ahmed M, Lam LT, Zhang H, Nomie K, Zhang L, Wang M. Genetic and Molecular Characterization of Ibrutinib-Resistant Mantle Cell Lymphoma: Designing Innovative Therapeutic Strategies Blood. 128: 1838-1838. DOI: 10.1182/Blood.V128.22.1838.1838 |
0.453 |
|
| 2016 |
Huang S, Nastoupil LJ, Guo H, Bell T, Ahmed M, Li CJ, Wang J, Liu Y, Zhang V, Kim CR, Boyle JN, Lorence EA, Lam LT, Chen Z, Zhang H, ... ... Nomie K, et al. Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma Blood. 128: 1837-1837. DOI: 10.1182/Blood.V128.22.1837.1837 |
0.53 |
|
| 2016 |
Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, ... ... Nomie K, et al. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial Blood. 128: 147-147. DOI: 10.1182/Blood.V128.22.147.147 |
0.363 |
|
| 2016 |
Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Fang B, Wang M, Nomie K. Abstract B18: B-cell lymphoma patient-derived xenograft models: The road to personalized therapy Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B18 |
0.478 |
|
| 2016 |
Zhang L, Pham L, Zhang H, Xie J, Tao W, Bell T, Chen Z, Nomie K, Fang B, Wang M. Abstract 4391: Overcoming primary ibrutinib resistance in mantle cell lymphoma Cancer Research. 76: 4391-4391. DOI: 10.1158/1538-7445.Am2016-4391 |
0.52 |
|
| 2015 |
Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet. Oncology. PMID 26640039 DOI: 10.1016/S1470-2045(15)00438-6 |
0.448 |
|
| 2015 |
Pham L, Zhang L, Tao W, Zhao D, Zhang H, Xie J, Wang J, Nomie K, Wang M. Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma Blood. 126: 707-707. DOI: 10.1182/Blood.V126.23.707.707 |
0.517 |
|
| 2015 |
Wang B, Zhang L, Pham L, Tao W, Zhang H, Xie J, Chen W, Cai Q, Zou D, Zhao D, Sun X, Liang R, Wang J, Nomie K, Fowler N, et al. The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma Blood. 126: 5126-5126. DOI: 10.1182/Blood.V126.23.5126.5126 |
0.481 |
|
| 2015 |
Wang M(, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin JR, Fayad L, Samaniego F, Turturro F, Chen W, Badillo M, Nomie KJ, DeLa Rosa M, Zhao D, Addison A, et al. Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update for a Phase II Clinical Trial Clinical Lymphoma Myeloma and Leukemia. 15: S65. DOI: 10.1016/J.Clml.2015.07.131 |
0.371 |
|
| Show low-probability matches. |